Results 181 to 190 of about 567,668 (313)

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. [PDF]

Pituitary
Hamblin R, White M, Fountas A, Karavitaki N.   +3 more
europepmc   +1 more source

Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent: benzothiazol-2-one 7-ethylamines

, 1987
Joseph Weinstock, Dimitri E. Gaitanopoulos, Orum D. Stringer, Robert G. Franz, J. Paul Hieble, Lewis B. Kinter, William A. Mann, Kathryn E. Flaim, George Gessner   +8 more
openalex   +1 more source

Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine [PDF]

, 2010
Alessandro Stefani, Salvatore Galati, Livia Brusa, Mariangela Pierantozzi, Antonella Peppe, Paolo Stanzione   +5 more
openalex   +1 more source

Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats

, 2021
Juho‐Matti Renko, Arun Kumar Mahato, Tanel Visnapuu, Konsta Valkonen, Mati Karelson, Merja H. Voutilainen, Märt Saarma, Raimo K. Tuominen, Yulia Sidorova   +8 more
openalex   +2 more sources

Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease

Journal of Parkinson's Disease, 2013
A. Djamshidian, S. O'sullivan, T. Foltynie, I. Avilés-Olmos, P. Limousin, A. Noyce, L. Zrinzo, A. Lees, B. Averbeck   +8 more
semanticscholar   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives

, 1985
Carl Kaiser, Penelope A. Dandridge, Eleanor Garvey, Kathryn E. Flaim, Robert L. Zeid, J. Paul Hieble   +5 more
openalex   +1 more source

Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data. [PDF]

BMC Pharmacol Toxicol
Mu L, Xu J, Ye X, Jiang Y, Yi Z.
europepmc   +1 more source

Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity

, 1983
Paul Anderson, John J. Baldwin, D. E. MCCLURE, G. F. Lundell, James Homer Jones, William C. Randall, Gregory E. Martin, Michael Williams, Jordan Hirshfield   +8 more
openalex   +1 more source